Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exact Sciences Cor (NQ: EXAS )

53.27 -0.25 (-0.47%)
Streaming Delayed Price Updated: 3:35 PM EDT, May 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Exact Sciences Cor

< Previous 1 2 Next >
Exact Sciences Earns 2024 Great Place To Work® Certification™
From Exact Sciences Corp.
Via Business Wire
Court Ruling Enables Exact Sciences to Proceed with Lawsuit against Geneoscopy
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Announces First-Quarter 2024 Results
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW® 2024
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Participate in May Investor Conference
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Names Aaron Bloomer as New Chief Financial Officer
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Schedules First Quarter 2024 Earnings Call
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner
From Exact Sciences Corp.
Via Business Wire
The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study
From Exact Sciences Corp.
Via Business Wire
Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon Cancer
From Exact Sciences Corp.
Via Business Wire
3 Hot Stocks Bought by Members of Congress: Follow the Money
Palo Alto Networks, Simon Property Group and JPMorgan Chase are the top three stocks bought by Members of Congress in February; 
Via MarketBeat
Exact Sciences to Participate in March Investor Conference
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Announces Fourth Quarter 2023 Results
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Schedules Fourth Quarter 2023 Earnings Call
From Exact Sciences Corp.
Via Business Wire
Time to buy these 3 healthcare companies that raised revenue guidance?
The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance. 
Via MarketBeat
Agilent Technologies and Exact Sciences Agree to Terms of Sale for Resolution Bioscience
From Agilent Technologies Inc.
Via Business Wire
ARKK: The Pros and Cons Of Buying Into Cathie's Best-Known ETF
If you're a believer in the progress of science and technology and feel strongly that our best days are still ahead, then a slice of ARKK could be tempting. 
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
Analysts Bullish On Exact Sciences' Advanced Cancer Screening
Exact Sciences sees a bump in stock price amid rising revenue and study results that show advancements to its flagship Cologuard colorectal screening product. 
Via MarketBeat
MarketBeat Week in Review – 5/15 - 5/19
Investors are battling stagflation as they wait for a recession, and the MarketBeat team continues to help you understand where to find opportunities 
Via MarketBeat
Topics Economy Electric Vehicles
Exposures Economy Electric Vehicles Interest Rates
Exact Sciences Serves Investors Exactly What They Wished For
Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The 
Via MarketBeat
A New Groundbreaking Tool to Detect Colon Cancer Earlier
A novel blood test for detecting colon cancer, the third most lethal type of cancer in the US, has been created. The Colorectal Cancer Screening Blood Test can identify cancer at early stages. This... 
Via PressReach
Exposures Product Safety
New Artificial Intelligence Tool Can Diagnose Colon Cancer
A new artificial intelligence (AI) model developed by Harvard Medical School and Taiwan’s National Cheng Kung University could provide much-needed clarity to clinicians presenting prognoses and... 
Via PressReach
Topics Artificial Intelligence Death
Exposures Artificial Intelligence Death Product Safety
Is Biotech Immunocore About To Make A 25% Price Move?
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. 
Via MarketBeat
Topics ETFs
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
Can gains in Tesla, Zoom, Exact Sciences, and other growth stocks set the stage for Cathie Woods' Ark Innovation Fund to stage a comeback in 2023? 
Via MarketBeat
Topics ETFs
Cathie Wood Is Buying These Stocks, Should You?
Cathie Wood is known for her deep understanding of tech companies and for holding aggressive long positions in her tech funds. Let's look at what she's buying. 
Via MarketBeat
Topics ETFs
Exact Sciences Corp Stock Price Is Trending Up Here's Why
Exact Science's stock price is shooting higher this week amid posting upward revisions for its revenue and earnings estimates for this quarter. 
Via MarketBeat
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.